aTyr Pharma (NASDAQ:LIFE) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of aTyr Pharma (NASDAQ:LIFE) in a research note issued to investors on Sunday. The firm set a “sell” rating on the biotechnology company’s stock.

Several other equities analysts also recently issued reports on LIFE. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective on shares of aTyr Pharma in a report on Tuesday, May 14th. Royal Bank of Canada decreased their price objective on shares of aTyr Pharma from $19.00 to $16.00 and set an “outperform” rating on the stock in a report on Friday, March 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $23.67.

aTyr Pharma Stock Up 2.7 %

LIFE stock opened at $1.90 on Friday. The firm has a market cap of $131.12 million, a PE ratio of -2.11 and a beta of 1.19. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.07 and a current ratio of 6.07. The firm’s fifty day moving average is $1.76 and its 200 day moving average is $1.66. aTyr Pharma has a one year low of $1.08 and a one year high of $2.45.

aTyr Pharma (NASDAQ:LIFE) last released its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.01. The firm had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.11 million. On average, research analysts forecast that aTyr Pharma will post -0.89 EPS for the current year.

Insider Buying and Selling at aTyr Pharma

In other aTyr Pharma news, Director Timothy Coughlin purchased 50,000 shares of the firm’s stock in a transaction dated Thursday, May 30th. The shares were purchased at an average cost of $1.75 per share, with a total value of $87,500.00. Following the completion of the purchase, the director now owns 56,000 shares in the company, valued at approximately $98,000. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other aTyr Pharma news, CEO Sanjay Shukla purchased 20,000 shares of the firm’s stock in a transaction dated Friday, May 31st. The shares were purchased at an average cost of $1.81 per share, with a total value of $36,200.00. Following the completion of the purchase, the chief executive officer now owns 136,548 shares in the company, valued at approximately $247,151.88. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Timothy Coughlin purchased 50,000 shares of the firm’s stock in a transaction dated Thursday, May 30th. The stock was acquired at an average cost of $1.75 per share, for a total transaction of $87,500.00. Following the completion of the purchase, the director now owns 56,000 shares of the company’s stock, valued at approximately $98,000. The disclosure for this purchase can be found here. Insiders have purchased a total of 75,000 shares of company stock valued at $132,650 over the last ninety days. Corporate insiders own 3.70% of the company’s stock.

Hedge Funds Weigh In On aTyr Pharma

Hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC raised its stake in aTyr Pharma by 5.1% during the third quarter. FMR LLC now owns 8,556,925 shares of the biotechnology company’s stock worth $13,520,000 after purchasing an additional 413,162 shares during the period. Granite Bay Wealth Management LLC purchased a new position in aTyr Pharma during the fourth quarter worth about $25,000. Pale Fire Capital SE raised its stake in aTyr Pharma by 425.8% during the fourth quarter. Pale Fire Capital SE now owns 293,706 shares of the biotechnology company’s stock worth $414,000 after purchasing an additional 237,849 shares during the period. Kingswood Wealth Advisors LLC purchased a new position in aTyr Pharma during the first quarter worth about $117,000. Finally, GSA Capital Partners LLP raised its stake in aTyr Pharma by 105.3% during the first quarter. GSA Capital Partners LLP now owns 224,147 shares of the biotechnology company’s stock worth $437,000 after purchasing an additional 114,983 shares during the period. 61.72% of the stock is owned by hedge funds and other institutional investors.

About aTyr Pharma

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.